Researchers at Whitehead Institute and Children's Hospital Boston have identified a protein, called Musashi 2, that is predictive of prognosis in acute myeloid leukemia and chronic myeloid leukemia patients. Diagnosed in an estimated 48,000 new patients annually, leukemia is blood cancer characterized by an overgrowth of certain blood cells. Musashi 2 and the cellular functions it affects could potentially represent therapeutic targets in certain types of leukemia.